title: Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative Experience.
authors.affiliation: Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor.
authors.forename: Geoffrey D
authors.initials: GD
authors.lastname: Barnes
authors.affiliation: Henry Ford Hospital, Detroit, Michigan.
authors.forename: Scott
authors.initials: S
authors.lastname: Kaatz
authors.affiliation: Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor.
authors.forename: Alexis
authors.initials: A
authors.lastname: Lopez
authors.affiliation: Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor.
authors.forename: Xiaokui
authors.initials: X
authors.lastname: Gu
authors.affiliation: Huron Valley Sinai-Cardiology and Vascular Associates, Commerce Township, Michigan.
authors.forename: Jay
authors.initials: J
authors.lastname: Kozlowski
authors.affiliation: Henry Ford Hospital, Detroit, Michigan.
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Krol
authors.affiliation: Frankel Cardiovascular Center, University of Michigan Health System, Ann Arbor.
authors.forename: James B
authors.initials: JB
authors.lastname: Froehlich
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D008824:Michigan / Q000453:epidemiology; D058996:Quality Improvement; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D014859:Warfarin / Q000009:adverse effects*
chemical_list: D000925:Anticoagulants; D014859:Warfarin